KR910003092A - 항체 정제 방법에 사용하기 위한 hcg펩티드 - Google Patents

항체 정제 방법에 사용하기 위한 hcg펩티드 Download PDF

Info

Publication number
KR910003092A
KR910003092A KR1019890010203A KR890010203A KR910003092A KR 910003092 A KR910003092 A KR 910003092A KR 1019890010203 A KR1019890010203 A KR 1019890010203A KR 890010203 A KR890010203 A KR 890010203A KR 910003092 A KR910003092 A KR 910003092A
Authority
KR
South Korea
Prior art keywords
pro
ser
lys
leu
asx
Prior art date
Application number
KR1019890010203A
Other languages
English (en)
Inventor
케이. 사린 비렌더
비이. 보드너 죤
Original Assignee
챨스 엠. 브록
애보트 레버러토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 챨스 엠. 브록, 애보트 레버러토리즈 filed Critical 챨스 엠. 브록
Publication of KR910003092A publication Critical patent/KR910003092A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음.

Description

항체 정제 방법에 사용하기 위한 HCG펩티드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. (a)항-hCG(human chorionic gonadotropin)항체를 함유하는 체액을 지지체상에 불용화된 hCG분석물-동족체와 접촉시킴으로써(여기에서, 상기 hCG분석물-동족체는 하기 서열을 함유하는 펩티드 서열이다: Axs112-Pro_Arg-Phe114-Glx-Asx-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Leu-Pro), 상기 펩티드 서열에 대해 특이적인 항-hCG 항체를 흡수시키고, (b) 이로써 특이적으로 흡수된 항-hCG항체를 유출시키는 단계를 포함함을 특징으로 하여, 항-hCG항체를 정제시키는 방법.
  2. 제1항에 있어서, Asx가 Asp이고 Glx가 Gin인 방법.
  3. 제1항 또는 2항에 있어서, 펩티드 서열이 말단 Lys잔기를 하나이상 추가로 함유하는 방법.
  4. 제1항에 있어서, 펩티드 서열이 하기 서열을 함유한 방법. Lys-Lys-Lys-Lys-Lys-Asx112-Pro-Arg-Phe114-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Leu-Pro.
  5. 제1항에 있어서, 펩티드 서열이 하기 서열을 함유한 방법. Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Leu-Pro-Lys-Lys-Lys-Lys-Lys.
  6. 하기 서열을 갖는 hCG분석물-동족체 펩티드.
    Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-He-Leu-Pro-Glx-Ser145-Leu-Pro. 상기서열에서, Asx는 Asp이고, Glx는 Gln이며, 상기 펩티드 서열은 말단 Lys 잔기를 하나이상 추가로 함유한다.
  7. 제6항에 있어서, 하기 서열을 갖는 팹티드. Lys-Lys-Lys-Lys-Lys-Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Leu-Pro.
  8. 제6항에 있어서, 하기 서열을 갖는 팹티드. Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Leu-Pro-Lys-Lys-Lys-Lys-Lys.
  9. (a)항-hCG항체를 함유하는 체액을 지지체상에 불용화된 hCG분석물-동족체와 접촉시킴으로써(여기에서, 상기 hCG분석물-동족체는 하기 서열을 함유하는 펩티드 서열이다: Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-lle-Leu-Pro-Glx-Ser145-Ler-Pro. 상기 펩티드 서열에 대해 특이적인 항-hCG 항체를 흡수시키고, (b) 이로써 특이적으로 흡수된 항-hCG항체를 유출시키는 단계를 포함함을 특징으로 하는, 항-hCG항체를 정제시키는 방법에 따라서 제조된 항체.
  10. 제9항에 있어서, 밀단 Lys잔기를 하나 이상 추가로 함유한 펩티드 서열이 상기 지지체에 부착된 항체.
  11. (a) 하기 서열을 갖는 hCG분석물-동족체 펩티드, 및 (b) 이 펩티드가 고정화 되어진 지지체를 포함함을 특징으로 하는, 항-hCG항체 정제용 친화성 컬럼. Asx112-Pro_Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asp-Thr-Pro140-lle-Leu-Pro-Gln-Ser145-Leu-Pro.
  12. 제11항에 있어서, 말단 Lys잔기를 하나이상 추가로 함유한 펩티드 서열이 상기 지지체에 부착된 친화성 컬럼.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010203A 1988-07-20 1989-07-19 항체 정제 방법에 사용하기 위한 hcg펩티드 KR910003092A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22168788A 1988-07-20 1988-07-20
US221,687 1988-07-20
US37573189A 1989-07-10 1989-07-10
US375,731 1989-07-10

Publications (1)

Publication Number Publication Date
KR910003092A true KR910003092A (ko) 1991-02-26

Family

ID=26916030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010203A KR910003092A (ko) 1988-07-20 1989-07-19 항체 정제 방법에 사용하기 위한 hcg펩티드

Country Status (9)

Country Link
US (1) US5451527A (ko)
EP (1) EP0351804B1 (ko)
JP (2) JP3055063B2 (ko)
KR (1) KR910003092A (ko)
AT (1) ATE143669T1 (ko)
AU (1) AU634479B2 (ko)
CA (1) CA1341014C (ko)
DE (1) DE68927283T2 (ko)
ES (1) ES2094725T3 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40835E1 (en) * 1992-01-16 2009-07-07 BioGenx Laboratories, Inc. Enhancement of immunochemical staining in aldehyde-fixed tissue
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
EP1566479A1 (en) * 2004-02-19 2005-08-24 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO Process for preparing a particulate material from mammalian hair and use thereof in paper or paperboard products
WO2012129519A1 (en) * 2011-03-23 2012-09-27 Deseret Biologicals, Inc. Formulations of diluted amino acid segments and methods for making same
US9573987B2 (en) * 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
WO2021097183A1 (en) * 2019-11-15 2021-05-20 President And Fellows Of Harvard College Device and method for analyte detection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313871A (en) * 1978-02-06 1982-02-02 Research Corporation Antigen for early pregnancy test and contraceptive vaccine
JPS576363A (en) * 1980-06-13 1982-01-13 Takeda Chem Ind Ltd Production of specific antibody
DK159276C (da) * 1980-03-31 1991-02-18 Takeda Chemical Industries Ltd Fremgangsmaade til isolering af specifikke antistoffer og enzym-immunbestemmelsesmetode med anvendelse af det isolerede antistof
EP0111216A3 (en) * 1980-03-31 1985-01-16 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor
EP0049898B2 (en) * 1980-10-15 1991-08-14 Takeda Chemical Industries, Ltd. Method for immunochemical assay and kit therefor
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4565687A (en) * 1981-11-16 1986-01-21 The Reagents Of The University Of Michigan Monoclonal antibodies specific for the unbound β subunit of human chorionic gonadotropin
ATE42317T1 (de) * 1983-07-29 1989-05-15 Henning Berlin Gmbh Voraktivierte kunststoffoberflaechen zur immobilisierung von organisch-chemischen und biologischen materialien, verfahren zur herstellung und verwendung derselben.
US4804626A (en) * 1986-10-22 1989-02-14 The General Hospital Corporation Immunometric assay for the detection of human chorionic gonadotropin

Also Published As

Publication number Publication date
US5451527A (en) 1995-09-19
DE68927283T2 (de) 1997-04-24
AU3825389A (en) 1990-01-25
EP0351804B1 (en) 1996-10-02
JPH02111792A (ja) 1990-04-24
CA1341014C (en) 2000-06-06
EP0351804A2 (en) 1990-01-24
JP3055063B2 (ja) 2000-06-19
ES2094725T3 (es) 1997-02-01
ATE143669T1 (de) 1996-10-15
JP3174041B2 (ja) 2001-06-11
EP0351804A3 (en) 1990-08-01
JP2000159800A (ja) 2000-06-13
AU634479B2 (en) 1993-02-25
DE68927283D1 (de) 1996-11-07

Similar Documents

Publication Publication Date Title
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
DE3750812D1 (de) Peptidzusammensetzung und Verfahren zum Nachweis von Antikörpern gegen HTLV-III.
KR937000141A (ko) 비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물
ES2076142T3 (es) Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.
ID28299A (id) Protein-protein reseptor seperti toll manusia metoda-metoda dan reagen-reagen yang berhubungan
KR920702723A (ko) 면역활성 펩티드 및 항체와 이것들의 항-알레르기 치료에의 이용
KR910003092A (ko) 항체 정제 방법에 사용하기 위한 hcg펩티드
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
NO901899D0 (no) Hiv-peptider, syntetiske hiv-antigener og immunoanalysekit
HUP9901411A2 (hu) Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
PT93178A (pt) Agente proteico anticanceroso
NO913037L (no) Peptider med for alfal-mikroglobulin karakteristiske antigene determinanter.
ES2062029T3 (es) Procedimiento de purificacion de proteinas.
ATE133422T1 (de) Peptide und deren benutzung
KR940008700A (ko) 사람형 모노클로날 항펩티드 항체 및 이것을 코드하는 dna
DE69224750D1 (de) Peptide und Antikörper zur Behandlung von rheumatoider Arthritis.
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
KR900018369A (ko) 사람의 응모성 성선 호르몬의 정제 방법
KR880013012A (ko) 항-프리-s- 항체의 분석법
FR2426055A1 (fr) Proteine purifiee associee au cancer

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid